<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ichicsr SYSTEM "\\amrndhw017\ESMLogs\icsr-xml-v2.1.dtd">
<ichicsr lang="en">
	<ichicsrmessageheader>
		<messagetype>psur</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4254112_P31</messagenumb>
		<messagesenderidentifier>PFIZERINC</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20130125151548</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>2</safetyreportversion>
		<safetyreportid>US-PFIZER INC-2013007834</safetyreportid>
		<primarysourcecountry>US</primarysourcecountry>
		<occurcountry>US</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>20130125</transmissiondate>
		<reporttype>1</reporttype>
		<serious>1</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>2</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>20130107</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>20130122</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>2</fulfillexpeditecriteria>
		<companynumb>US-PFIZER INC-2013007834</companynumb>
		<medicallyconfirm>1</medicallyconfirm>
		<primarysource>
			<reportertitle>Dr.</reportertitle>
			<reportergivename>Thomas</reportergivename>
			<reportermiddlename>M</reportermiddlename>
			<reporterfamilyname>Blum</reporterfamilyname>
			<reporterorganization>Mystic Medical group</reporterorganization>
			<reporterstreet>200 Sandy Hollow Road</reporterstreet>
			<reportercity>Mystic</reportercity>
			<reporterstate>CT</reporterstate>
			<reporterpostcode>06355</reporterpostcode>
			<reportercountry>US</reportercountry>
			<qualification>1</qualification>
		</primarysource>
		<primarysource>
			<reportergivename>Theresa</reportergivename>
			<reportermiddlename>C</reportermiddlename>
			<reporterfamilyname>Wilson</reporterfamilyname>
			<reporterorganization>Pfizer</reporterorganization>
			<reporterdepartment>NCE PDM ADME CoE</reporterdepartment>
			<reportercountry>US</reportercountry>
			<qualification>5</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>PFIZERINC</senderorganization>
			<senderfamilyname>Head Drug Safety Surveillance</senderfamilyname>
			<senderstreetaddress>150 East 42nd Street</senderstreetaddress>
			<sendercity>New York</sendercity>
			<senderstate>New York</senderstate>
			<senderpostcode>10017</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>2127335544</sendertel>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receivertitle>Mr</receivertitle>
			<receivergivename>Roger</receivergivename>
			<receiverfamilyname>Goetsch</receiverfamilyname>
			<receiverstreetaddress>8201 Corporate Drive, Suite 540</receiverstreetaddress>
			<receivercity>Landover</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20785</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>3019189580</receivertel>
			<receivertelextension>194</receivertelextension>
			<receivertelcountrycode>001</receivertelcountrycode>
			<receiverfax>3019183134</receiverfax>
			<receiverfaxcountrycode>001</receiverfaxcountrycode>
		</receiver>
		<patient>
			<patientinitial>PRIVACY</patientinitial>
			<patientsex>1</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Tendon rupture</patientepisodename>
				<patientmedicalcomment>while on Lipitor</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>He ruptured his right quadriceps tendon</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Tendon rupture</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Tendon rupture</reactionmeddrapt>
				<reactionstartdateformat>602</reactionstartdateformat>
				<reactionstartdate>2011</reactionstartdate>
				<reactionoutcome>1</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization>1</drugcharacterization>
				<medicinalproduct>Lipitor</medicinalproduct>
				<obtaindrugcountry>US</obtaindrugcountry>
				<drugauthorizationnumb>20-702</drugauthorizationnumb>
				<drugauthorizationcountry>US</drugauthorizationcountry>
				<drugauthorizationholder>Pfizer, Inc.</drugauthorizationholder>
				<drugstructuredosagenumb>10</drugstructuredosagenumb>
				<drugstructuredosageunit>003</drugstructuredosageunit>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition>804</drugintervaldosagedefinition>
				<drugdosagetext>10 mg, Daily</drugdosagetext>
				<drugdosageform>Film-coated tablet</drugdosageform>
				<drugadministrationroute>048</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Blood cholesterol increased</drugindication>
				<drugstartdateformat>602</drugstartdateformat>
				<drugstartdate>2006</drugstartdate>
				<actiondrug>4</actiondrug>
				<activesubstance>
					<activesubstancename>ATORVASTATIN CALCIUM</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Tendon rupture</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Tendon rupture</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>N/A</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>This is a spontaneous report initially from a contactable consumer, a Pfizer employee (patient's wife) and then from a contactable physician. A male patient of an unspecified age and ethnicity started to receive atorvastatin calcium (LIPITOR) oral from 2006 with duration of treatment of 7 years and ongoing (initially reported from 20 years ago) at 10 mg, daily for increased cholesterol. Medical history included that the patient ruptured left quad tendon while on atorvastatin calcium (trade name LIPITOR) on an unknown date. There were no drug allergies and family history. There were no concomitant medications and relevant drug history. The patient ruptured his right quadriceps tendon in 2011. The action taken in response to the event for atorvastatin calcium was dose not changed. In the initial report, it was reported that the patient attended a pre-operative visit on 07Jan2013 to obtain clearance for surgery to repair the ruptured quadriceps tendon in his left leg. His physician informed him that tendon rupture was a side effect of atorvastatin calcium and decided to pull him off it. In the further report the physician confirmed that therapeutic measures taken as a result of was surgical repair. The outcome of the event was recovered. In the report as of 22Jan2013, the physician confirmed the occurrence of the event reported and assessed there was a reasonable possibility that the event was related to suspect product.

Follow-up (22Jan2013): New information received from a contactable physician includes: product detail data, relevant medical history, concomitant medications data, event onset date, action taken data, treatment data, event outcome and causality assessment of the physician.

Follow-up attempts completed. No further information expected.</narrativeincludeclinical>
				<sendercomment>Based on available information, a possible contributory role of the subject drug can not be excluded for the reported event.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr>
